# R1 Clinical-Safety Review — pleomorphic_xanthoastrocytoma (management narrative)

VERDICT: APPROVE (with one Important advisory to fix before merge; non-blocking)

goldens changed: no (intended: n/a — reference narrative text, no engine/calculator/interaction logic touched)

Adversarial verdict file (.verdict.md): NOT PRESENT. No prior ISSUES to reconcile; the
mandatory-REVISE gate for still-present flagged claims does not apply.

## 1. SAFETY — pass
- No unsafe, harmful, or absolute directive. Curative-intent language is correctly scoped to
  "newly diagnosed, resectable, lower-grade (CNS WHO grade 2)" disease and control/palliative for
  grade 3/unresectable/recurrent. No statement would cause harm if followed.
- No critical-alert or dose-limit logic here; nothing dismissable.

## 2. GROUNDING — pass
- The draft is scrupulous about attribution: every PXA-specific extrapolation is explicitly labelled
  "general oncology standard, not from DeVita's section on this disease," and it states plainly that
  DeVita has no dedicated PXA section (folded into "well-circumscribed"/"astroglial variant" low-grade
  glioma and general BRAF-mutant glioma discussion). No DeVita mis-attribution detected.
- BRAF-inhibitor basket-trial claim (durable response, xanthoastrocytoma named, response/treatment
  duration exceeding one year overall and two years in xanthoastrocytoma; responses in a minority) is
  consistent with the VE-BASKET data DeVita cites. Grounded.
- BRAF+MEK combination framed as a class-level option for recurrent/unresectable/anaplastic disease,
  correctly grounded in DeVita's broader BRAF-mutant glioma discussion, not a PXA-specific trial.
  Consistent with NCCN CNS standard of care.
- No fabricated or outdated regimen.

## 3. DOSE-FREE — pass
- No numeric dose leaked. "Grade 2/3", "one/two years", "higher radiotherapy doses are warranted"
  (word only, no number) are grade/duration/qualitative, not dosing. No mg, mg/m2, AUC, or numbered
  schedule present. Doses correctly deferred to structured templates.

## 4. SCOPE — pass
- Consistently hedged as decision-support ("reasonable option," "consider," "case-by-case in a
  multidisciplinary setting," referral triggers). Not directive.

## 5. ADVISORY FLAGS
- None still-present from an adversarial pass (no verdict file existed).

## Important (fix, non-blocking)
- Line 59 / title: "BRAF V600E mutation is a defining molecular feature of PXA." Overstated. BRAF
  V600E is characteristic/common in PXA (~60-80% of cases), not universal and not a WHO defining
  criterion. Reword to "characteristic/common molecular feature" to avoid implying all PXA are
  BRAF-mutant or that a BRAF-wildtype result excludes PXA. Not harmful (the draft still recommends
  molecular/BRAF testing), hence Important, not Critical.

## Advisory
- Heavy reliance on ganglioglioma-section extrapolation is honestly labelled; acceptable. Consider
  confirming the radiotherapy "adjuvant after subtotal resection" framing also aligns with the cited
  NCCN CNS reference edition when the structured protocol is built.

APPROVE: clinically safe, dose-free, appropriately scoped, and grounded with no DeVita
mis-attribution. Recommend applying the one Important wording fix ("defining" -> "characteristic/
common") at merge.
